Stocks · Health care · Pharmaceutical Preparations

Ovid Therapeutics Inc.

OVID Clue Score44
United States Fiscal year ends December CIK 0001636651 Results filed 18 Mar 2026

What the insiders did Net buying

By person

14 insiders · 17 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Takeda Pharmaceutical Co Ltd entity
10% owner
$5.00M (1)
—
+$5.00M
12,750,000
$18.49M
+34.2%
Jeremy M Levin
Executive Chairman
$509.57K (5)
—
+$509.57K
3,770,509
$5.47M
−9.9%
Amit Rakhit
President and CMO
—
$126.20K (1) scheduled
−$126.20K
726,823
$1.05M
0.0%
Karen Bernstein
Director
$82.51K (2)
—
+$82.51K
20,000
$29.00K
—
Jason Tardio
Chief Operating Officer
—
$37.29K (1)
−$37.29K
28,125
$40.78K
+62.2%
Douglas E Williams
Director
$32.44K (1)
—
+$32.44K
5,000
$7.25K
—
Margaret A. Alexander
President and CEO
$4.97K (1)
$19.86K (2)
−$14.89K
61,750
$89.54K
+119.6%
Jeffrey A Rona
Cbfo
—
$14.57K (2)
−$14.57K
156,313
$226.65K
+443.6%
Matthew During
Director
—
—
—
4,679,406
$6.79M
+0.6%
Stelios Papadopoulos
Director
—
—
—
217,578
$315.49K
+8.8%
Charles Ross Carter
Chief Financial Officer
—
—
—
94,375
$136.84K
+112.7%
Thomas Michael Perone
General Counsel, Secretary
—
—
—
28,125
$40.78K
—
Kevin Joseph Fitzgerald
Director
—
—
—
17,578
$25.49K
—
Bart Friedman
Director
—
—
—
8,789
$12.74K
—

No percentages here. This company's share count has moved by a factor of 2.7 over the window, from 71,109,514 to 195,297,857 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.